{"title":"DNA Dissipative System for Controlled Release of Immunostimulatory CpG Oligodeoxynucleotides","authors":"Aman Ishaqat, Xiaofeng Zhang, Andreas Herrmann","doi":"10.1002/anbr.202400082","DOIUrl":null,"url":null,"abstract":"<p>Herein, a dissipative system tailored for the controlled loading and release of CpG oligodeoxynucleotides (CpG ODNs), known for their pharmacological immunostimulatory properties, is reported. The approach involves multiple cycles of deactivation and activation of the CpG ODNs via its hybridization with a complementary fuel strand, followed by its selective release mediated by the enzymatic activity of T7 exonuclease. The autonomous and temporal behavior of this dissipative system can be tuned by three factors: the design of the fuel strand and its concentration that governs the kinetics of the forward hybridization reaction, as well as the concentration of T7 exonuclease, which regulates the backward energy dissipation reaction. Furthermore, the enzyme's tolerance toward waste accumulation is demonstrated, and the system's robust performance when utilizing various fuel strands in alternating fashion is showcased. The findings underscore the potential of this approach for precise and programmable delivery of therapeutic nucleic acids in multiple cycles, with implications for enhancing immunotherapeutic strategies in which controlled kinetics of the nucleic acid is highly desired.</p>","PeriodicalId":29975,"journal":{"name":"Advanced Nanobiomed Research","volume":"4 11","pages":""},"PeriodicalIF":4.0000,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/anbr.202400082","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced Nanobiomed Research","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/anbr.202400082","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0
Abstract
Herein, a dissipative system tailored for the controlled loading and release of CpG oligodeoxynucleotides (CpG ODNs), known for their pharmacological immunostimulatory properties, is reported. The approach involves multiple cycles of deactivation and activation of the CpG ODNs via its hybridization with a complementary fuel strand, followed by its selective release mediated by the enzymatic activity of T7 exonuclease. The autonomous and temporal behavior of this dissipative system can be tuned by three factors: the design of the fuel strand and its concentration that governs the kinetics of the forward hybridization reaction, as well as the concentration of T7 exonuclease, which regulates the backward energy dissipation reaction. Furthermore, the enzyme's tolerance toward waste accumulation is demonstrated, and the system's robust performance when utilizing various fuel strands in alternating fashion is showcased. The findings underscore the potential of this approach for precise and programmable delivery of therapeutic nucleic acids in multiple cycles, with implications for enhancing immunotherapeutic strategies in which controlled kinetics of the nucleic acid is highly desired.
期刊介绍:
Advanced NanoBiomed Research will provide an Open Access home for cutting-edge nanomedicine, bioengineering and biomaterials research aimed at improving human health. The journal will capture a broad spectrum of research from increasingly multi- and interdisciplinary fields of the traditional areas of biomedicine, bioengineering and health-related materials science as well as precision and personalized medicine, drug delivery, and artificial intelligence-driven health science.
The scope of Advanced NanoBiomed Research will cover the following key subject areas:
▪ Nanomedicine and nanotechnology, with applications in drug and gene delivery, diagnostics, theranostics, photothermal and photodynamic therapy and multimodal imaging.
▪ Biomaterials, including hydrogels, 2D materials, biopolymers, composites, biodegradable materials, biohybrids and biomimetics (such as artificial cells, exosomes and extracellular vesicles), as well as all organic and inorganic materials for biomedical applications.
▪ Biointerfaces, such as anti-microbial surfaces and coatings, as well as interfaces for cellular engineering, immunoengineering and 3D cell culture.
▪ Biofabrication including (bio)inks and technologies, towards generation of functional tissues and organs.
▪ Tissue engineering and regenerative medicine, including scaffolds and scaffold-free approaches, for bone, ligament, muscle, skin, neural, cardiac tissue engineering and tissue vascularization.
▪ Devices for healthcare applications, disease modelling and treatment, such as diagnostics, lab-on-a-chip, organs-on-a-chip, bioMEMS, bioelectronics, wearables, actuators, soft robotics, and intelligent drug delivery systems.
with a strong focus on applications of these fields, from bench-to-bedside, for treatment of all diseases and disorders, such as infectious, autoimmune, cardiovascular and metabolic diseases, neurological disorders and cancer; including pharmacology and toxicology studies.